Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 21, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

- Suprachoroidal Injection of CLS-AX 0.1 mg Dose Well-Tolerated in Cohort 2 with No Treatment Related Adverse Events –- Consistent Safety Profile Observed in Cohorts 1 and 2 Supports Advancement to...
December 13, 2021 16:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Added to the Nasdaq Biotechnology Index

ALPHARETTA, Ga., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
November 16, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings

ALPHARETTA, Ga., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
November 11, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Participate in Upcoming Investor Events in November and December 2021

ALPHARETTA, Ga., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
November 10, 2021 16:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Third Quarter 2021 Financial Results and Provides Corporate Update

- XIPERE™ is First FDA-Approved Product for Injection into the Suprachoroidal Space - - Approval-Related Milestones to Provide $19 Million in Non-Dilutive Funding - - Continued Progress in...
October 28, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Wednesday, November 10, 2021

ALPHARETTA, Ga., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
October 13, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Delivers Podium and Poster Presentations at the American Society of Retina Specialists (ASRS) Annual Meeting

ALPHARETTA, Ga., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
October 04, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Multiple Poster Presentations at the Retina Society 54th Annual Scientific Meeting

ALPHARETTA, Ga., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
September 21, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

ALPHARETTA, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
September 09, 2021 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Expands XIPERE™ License Agreement with Arctic Vision to Include Australia, New Zealand, India and ASEAN Countries

ALPHARETTA, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...